Viridian Therapeutics, Inc.\DE·4

Feb 10, 4:54 PM ET

Katz Barrett 4

4 · Viridian Therapeutics, Inc.\DE · Filed Feb 10, 2023

Insider Transaction Report

Form 4
Period: 2023-02-08
Katz Barrett
Chief Medical Officer
Transactions
  • Award

    Stock Option (Right to Buy)

    2023-02-08+108,000108,000 total
    Exercise: $34.20Exp: 2033-02-08Common Stock (108,000 underlying)
Footnotes (1)
  • [F1]The option vests in equal monthly installments through February 8, 2027, subject to the Reporting Person's continued service to Issuer through each vesting date.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION